A Survey-Based Exploration of Biopharma's Shifting Landscape and the Crucial Role of Direct-to-Patient Trials
In the ever-changing landscape of clinical research, transformation is driven by forces of economic challenges, increasingly slender budgets, and the persistent hurdle of patient recruitment. The biopharma industry is facing an evolution that necessitates seamless integration of remote study conduct and virtual strategies into the fabric of clinical trials.
Download Science 37’s Future of Clinical Trials White Paper, 2023, a comprehensive analysis shaped by the perspectives of over 100 clinical trial executives spanning all therapeutic areas. This report captures the evolving landscape of clinical trials and sheds light on what is driving clinical research changes, with new findings showing the importance of bringing trials to patients as the path forward.
Access the white paper to discover:
- Top challenges in clinical development
- Industry utilization of virtual and hybrid approaches
- Roadblocks to adoption and how to overcome them
- The rise of virtual sites and the benefits they deliver
Authors
Jonathan Cotilar, MD, Chief Medical Officer, Science 37
Darcy Forman, Chief Delivery Officer, Science 37
A Survey-Based Exploration of Biopharma's Shifting Landscape and the Crucial Role of Direct-to-Patient Trials
In the ever-changing landscape of clinical research, transformation is driven by forces of economic challenges, increasingly slender budgets, and the persistent hurdle of patient recruitment. The biopharma industry is facing an evolution that necessitates seamless integration of remote study conduct and virtual strategies into the fabric of clinical trials.
Download Science 37’s Future of Clinical Trials White Paper, 2023, a comprehensive analysis shaped by the perspectives of over 100 clinical trial executives spanning all therapeutic areas. This report captures the evolving landscape of clinical trials and sheds light on what is driving clinical research changes, with new findings showing the importance of bringing trials to patients as the path forward.
Access the white paper to discover:
- Top challenges in clinical development
- Industry utilization of virtual and hybrid approaches
- Roadblocks to adoption and how to overcome them
- The rise of virtual sites and the benefits they deliver
Authors
Jonathan Cotilar, MD, Chief Medical Officer, Science 37
Darcy Forman, Chief Delivery Officer, Science 37
Decentralized Clinical Trials — Is There a Positive Return on Investment on a Virtual Site?
Across the Life Sciences industry, there has been much talk about the cost and value of decentralized clinical trials (DCT) and the potential return on investment (ROI) when the expedited time to commercialization is considered. When faced with an 80% delay rate due to a myriad of reasons, the industry is potentially facing more than 51,000 delayed trials globally— not including new trials beginning in upcoming months and years.
With most studies likely including a combination of traditional and virtual sites, Science 37 has examined the cost and value impact of differing numbers of brick-and-mortar sites deployed in combination with a virtual site.
Download our newest white paper and learn more about:
- Key drivers of decentralized clinical trial value
- Scenarios that show the value delivered with a mix of traditional and virtual sites
- And how to optimize trial design to meet key objectives such as time, cost, risk mitigation, and more.
How to Meet the FDA Diversity Action Plan Guidance
The pending FDA Guideline’s intention is clear—pharma companies must plan, report and collaborate to improve diverse representation in clinical trials. Most sponsors have assessed their capability and are gearing up for action. However, “Analysis by Paralysis” or even “Trial and Error,” should not stand in the way of progress.
For most companies, transformation is needed, but a single, one-size fits all solution might not be the answer to improving diversity in research. Flexible and interactive strategies must be implemented to drive a solution that delivers results. In this whitepaper, Science 37 Diversity and Inclusion leaders share tips and strategies on how to achieve diversity in clinical trials.
Learn how to:
- Make diversity part of your culture
- Engage clinical trial participants as customers
- Continuously monitor for patient experience—while improving and adapting
- And how leveraging decentralized clinical trials can improve patient access and reach.
Fill out the form now to access these insights.